The anti-mouse CEACAM1 Ab, CC1, has been used in a number of preclinical studies to evaluate CEACAM1 as a potential anti-tumor target [17, 19, 21, 23], however we were not able to find any published studies describing the ligand blocking capacity of this antibody. This evidence concerns the gene CEACAM1 and neoplasm.